大行評級|麥格理:下調維他奶目標價至6.9港元 下調2025至27財年盈測
麥格理髮表報吿指,雖然飲料市場充滿挑戰,但仍預計維他奶2025財年上半年營收將增長2.2%,營業利潤則按年增長9.3%。集團在內地市場未能免受不利天氣及市場競爭的影響,但香港市場的表現仍具韌力。麥格理將維他奶2025至2027財年盈利預測分別下調38%、38%及30%,以考慮不利天氣、市場競爭及營運去槓桿化的因素,將維他奶目標價下調27%至6.9港元,此相當於預測2026財年市盈率6.9倍,評級“跑贏大市”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.